🧪 Syngene International Q2 FY2025-26 Results: Profit Down 37%, Revenue Up 2% — Detailed Analysis and Management Outlook

Syngene International Ltd., a leading contract research, development, and manufacturing (CRDMO) company under the Biocon Group, announced its Q2 FY2025-26 results showcasing steady revenue growth but a steep drop in profits due to margin pressure and biological manufacturing adjustments.

While the Research Services business continued to perform well, the Biologics Manufacturing segment saw headwinds from inventory correction and underutilization. Despite short-term challenges, management reaffirmed its full-year guidance and remains confident in long-term growth.

📊 Syngene International Q2 FY2025-26 Financial Performance at a Glance

(Sources: Company filings, Moneycontrol, Business Standard, IndiaMedToday)

💡 Key Takeaways from Q2 FY2025-26

• Revenue: ₹911 crore (↑ 2% YoY) — steady but below expectations.

• Net Profit: ₹67 crore (↓ 37% YoY) — impacted by lower biologics utilization.

• EBITDA: ₹215 crore (↓ 18% YoY).

• EBITDA Margin: 23.2% vs 28.8% last year (down 560 bps).

• Segment Impact: Biologics slowdown offset by Research Services growth.

• Full-Year Guidance: Maintained — mid-single-digit revenue growth and mid-20s EBITDA margins.

🧾 Detailed Segment-Wise Performance

🔬 1. Research Services: The Growth Engine Remains Strong

Syngene’s Discovery and Development Services continued to deliver steady performance in Q2 FY26. This segment, which forms the company’s core revenue stream, benefited from increased client engagements and steady demand from global pharma and biotech clients.

• Revenue from this segment showed mid-single-digit growth.

• Client retention remained high, with repeat business forming over 80% of revenues.

• Expansion in chemistry and biologics research platforms contributed to underlying stability.

This business provided revenue resilience, offsetting weakness in the manufacturing side.

🧫 2. Biologics Manufacturing: Temporary Headwinds

The Biologics business, which has been a strategic focus area, faced headwinds due to inventory correction and lower capacity utilization.

• Revenue from biologics was down significantly YoY, pulling down margins.

• The company attributed this to customer destocking and temporary adjustments in production schedules.

• Lower fixed-cost absorption in large biologics facilities hurt EBITDA margins.

However, the company emphasized that the fundamentals remain strong, and new biologics and ADC (Antibody-Drug Conjugate) projects will drive recovery.

“Our Q2 performance was driven by underlying growth in Research Services, which compensated for the anticipated inventory correction in Biologics Manufacturing,”
said Peter Bains, Managing Director and CEO, Syngene International Ltd.

⚗️ 3. Development & Manufacturing: Strategic Expansion Continues

The Development and Manufacturing division, including small-molecule manufacturing, remained stable despite global supply chain challenges.

Syngene continues to invest in capacity enhancement and process technology, especially for high-potency APIs (HPAPIs) and ADC conjugation facilities, positioning itself as a trusted partner for global pharma companies.

The company commissioned a new bioconjugation suite in Bengaluru, capable of producing Antibody-Drug Conjugates — a fast-growing segment in precision oncology manufacturing.

💰 Profitability and Margin Analysis

Analysis:
While revenue grew marginally, profitability suffered due to lower biologics output and underutilization of high-cost manufacturing assets. Research services helped mitigate some of this impact, but overall profit margins fell sharply YoY.

📈 Quarter-on-Quarter Comparison

Despite a 4% sequential revenue improvement, profit dropped due to product mix and normalization of earlier quarter benefits.

🧠 Management Commentary and Outlook

🗣️ CEO’s Statement – Peter Bains

“Our second quarter performance was impacted by expected adjustments in biologics manufacturing, but research services remain on track. We continue to invest in expanding our capabilities in new modalities such as peptides and ADCs, which will be key growth drivers.”

💼 CFO Commentary – Stable Guidance Maintained

“We are maintaining our full-year guidance for FY26, expecting mid-single-digit revenue growth and mid-20s EBITDA margins. Our balance sheet remains strong, and we are confident of delivering improved performance in H2.”

🔹 Key Management Highlights:

• No change to FY26 growth guidance.

• Continued capex investment in ADC and biologics capacity.

• Focus on productivity and cost optimization.

• Targeting long-term partnerships with top global biotech firms.

🧭 Strategic Focus Areas

1. Diversification Beyond Biologics: Syngene is focusing on expanding its peptide and ADC manufacturing facilities to reduce dependence on single modalities.

2. Research-driven Growth: Continued investment in small-molecule discovery platforms.

3. Capacity Expansion: New manufacturing units in Bengaluru and Mangalore to be operational by FY27.

4. Digitalization: Upgrading automation and AI-driven analytics in R&D for efficiency.

5. Global Partnerships: Strengthening collaborations with major biotech clients in the US and Europe.

🧩 Analyst Reactions

Market analysts noted that while Syngene’s profitability decline is concerning, the company’s steady revenue growth and commitment to expansion in biologics and ADCs are long-term positives.

• Motilal Oswal: “Biologics normalization was expected; focus should be on utilization recovery.”

• ICICI Securities: “H2 FY26 could see margin stabilization as new orders ramp up.”

• HDFC Securities: “Structural growth story intact; long-term investors should stay put.”

🧮 Balance Sheet and Capex Position

• Net Debt: ₹ Nil (Company remains net-debt-free).

• Cash & Investments: ~₹900 crore as of September 2025.

• Capex: ₹150 crore in Q2, largely towards biologics and ADC facilities.

• Return on Equity (ROE): 12.1% (down from 15.6% last year).

Syngene’s robust balance sheet allows it to continue investing even amid short-term margin pressure — a key advantage over smaller CDMOs.

🔍 Key Factors to Watch Going Forward

1. Recovery in Biologics Volumes: How quickly the inventory correction resolves.

2. EBITDA Margin Rebound: Improvement expected in H2 FY26.

3. New Customer Wins: From global biotech clients.

4. ADC and Peptide Pipeline Growth: Ramp-up of new high-value modalities.

5. Global Biotech Funding: Impacts CDMO order flows.

💬 Conclusion: A Transitional Quarter for Syngene

The Q2 FY2025-26 results mark a transition phase for Syngene International Ltd. — balancing short-term profit challenges with long-term growth investments.

Revenue rose 2% YoY to ₹911 crore, but net profit fell 37% to ₹67 crore as biologics utilization dipped. Despite this, the company’s strong research services business, stable guidance, and ongoing investments in advanced biomanufacturing signal optimism for the future.

As India’s leading integrated research and manufacturing partner for global pharma, Syngene’s fundamentals remain robust.
The focus now shifts to margin recovery and capacity utilization in the biologics segment, which will define the company’s trajectory in FY26 and beyond.